Michael Gelband’s Haemonetics HAE Stock Holding History

Michael Gelband’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,000	Closed	-$1.75M	–	2115
2020 Q3	$1.75M	Buy	+20,000	New	+$1.75M	0.03%	447

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's HAE Position: Q2 2026 in Review

Michael Gelband sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 47,750 shares — an estimated $2.69M sold.

Michael Gelband first reported a position in HAE in Q4 2019 and held it in 17 quarters. The position peaked at $15.2M in Q3 2025. 327 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Michael Gelband reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 47,750 Haemonetics shares in Q2 2026, an estimated $2.69M.
Michael Gelband first reported a position in Haemonetics in Q4 2019 and held it in 17 quarters.
Michael Gelband's Haemonetics position peaked at $15.2M in Q3 2025.
327 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.